These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 30900911)

  • 21. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
    Willemse SB; Baak LC; Kuiken SD; van der Sluys Veer A; Lettinga KD; van der Meer JT; Depla AC; Tuynman H; van Nieuwkerk CM; Schinkel CJ; Kwa D; Reesink HW; van der Valk M
    J Viral Hepat; 2016 Dec; 23(12):950-954. PubMed ID: 27405785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    Moradpour D; Grakoui A; Manns MP
    J Hepatol; 2016 Oct; 65(1 Suppl):S143-S155. PubMed ID: 27641984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study.
    Nam JY; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Bae SH; Ki M; Choi HY; Lee EY; Jeong SH
    Gut Liver; 2020 Mar; 14(2):207-217. PubMed ID: 31158950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection.
    Martinez MA; Franco S
    Adv Exp Med Biol; 2021; 1322():139-157. PubMed ID: 34258740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals.
    Nahon P; Cobat A
    Hum Genet; 2020 Jun; 139(6-7):855-863. PubMed ID: 32100095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.
    Virzì A; Roca Suarez AA; Baumert TF; Lupberger J
    Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31501266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C-A clinical review.
    Wang LS; D'Souza LS; Jacobson IM
    J Med Virol; 2016 Nov; 88(11):1844-55. PubMed ID: 27097298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why is viral eradication so important in patients with HCV-related cirrhosis?
    Velosa J
    Antivir Ther; 2017; 22(1):1-12. PubMed ID: 27553973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients.
    Komatsu F; Takasaki K
    Liver; 1999 Oct; 19(5):375-80. PubMed ID: 10533794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hepatitis C virus infection. From clinical guidelines to clinical practice and personalization of cure.].
    Toniutto P
    Recenti Prog Med; 2018 Jan; 109(1):33-37. PubMed ID: 29451520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.
    Daniel KE; Said A
    Curr Gastroenterol Rep; 2018 Apr; 20(5):20. PubMed ID: 29623506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection.
    Mohanty A; Salameh S; Butt AA
    Curr HIV/AIDS Rep; 2019 Oct; 16(5):389-394. PubMed ID: 31482299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?
    Cabibbo G; Celsa C; Cammà C; Craxì A
    Liver Int; 2018 Dec; 38(12):2108-2116. PubMed ID: 29935096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.
    Majumdar A; Kitson MT; Roberts SK
    Drugs; 2015 May; 75(8):823-34. PubMed ID: 25943281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Interferon-Free, Direct-Acting Antivirals Treatment for Japanese Patients with Chronic Hepatitis C Infection and Chronic Kidney Disease.
    Atsukawa M; Kondo C; Kawano T; Okubo T; Arai T; Nakagawa-Iwashita A; Itokawa N; Iwakiri K
    J Nippon Med Sch; 2021 Jun; 88(3):163-170. PubMed ID: 33692289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.